Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study

doi:10.3748/wjg.v27.i17.2025

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5779)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

451

WORD

186

HTML

3121

Figures (1-3)

491

Tables (1-4)

243

Sum=4492

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

404

Download

883

Sum=1287

May 7, 2021 (publication date) through Sep 19, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. May 7, 2021; 27(17): 2025-2038
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.2025

Table 1 Comparison of the clinical characteristics of patients with and without hepatocellular carcinoma

Characteristic	no-HCC group (n = 145)	HCC group (n = 121)	P value
Age ≥ 60 yr, n (%)	41 (28.3)	64 (52.9)	< 0.001
Male, n (%)	99 (68.3)	91 (75.2)	0.133
Etiology of liver cirrhosis, n (%)
HBV	101 (60.7)	76 (62.8)	0.363
HBV + alcohol	31 (21.4)	45 (37.2)	0.006
HBV + HEV	1 (0.6)	0 (0.0)	-
HBV + schistosome	1 (0.6)	0 (0.0)	-
Smoking history, n (%)	21 (14.5)	51 (42.1)	< 0.001
Family history of HBV-related HCC, n (%)	10 (6.9)	23 (19.0)	0.004
Medication history
Duration of NA treatment, yr, median (P₂₅, P₇₅)	3.9 (2.1, 5.8)	5.4 (2.3, 6.9)	0.067
LAM resistance, n (%)	18 (12.4)	27 (22.3)	0.021
HBsAg level, IU/L, median (P₂₅, P₇₅)	255.0 (56.0, 678.0)	269.0 (67.0, 656.0)	0.456
HBeAg positive, n (%)	37 (25.5)	21 (17.4)	0.136
HBV DNA negative, n (%)	67 (46.2)	39 (32.2)	0.033
ALB, U/L	36.29 ± 7.98	33.34 ± 6.62	0.002
ALT, U/L, median (P₂₅, P₇₅)	27.00 (18.00, 37.00)	32.00 (21.27, 62.00)	0.006
AST, U/L, median (P₂₅, P₇₅)	33.00 (23.00, 47.00)	44.50 (31.65, 96.85)	< 0.001
GGT, U/L, median (P₂₅, P₇₅)	33.00 (20.00, 46.00)	61.50 (32.75, 160.75)	< 0.001
ALP, U/L, median (P₂₅, P₇₅)	99.00 (73.00, 126.00)	134.50 (92.00, 198.85)	< 0.001
TB, μmol/L, median (P₂₅, P₇₅)	20.41 (13.81, 44.60)	24.46 (16.60, 42.80)	0.192
FBS, mmol/L, median (P₂₅, P₇₅)	5.17 ± 0.68	6.99 ± 1.31	0.025
Ascites, n (%)	33 (20.0)	43 (34.7)	0.022
Child-Pugh class, n (%)
A	81 (55.9)	55 (45.5)	0.001
B	38 (26.2)	26 (21.5)	0.561
C	26 (17.9)	40 (33.1)	0.002
AFP ≥ 20 μg/L, n (%)	14 (9.7)	56 (46.3)	< 0.001
PT s, median (P₂₅, P₇₅)	13.25 (11.80, 14.20)	13.51 (12.41, 15.02)	0.475

AFP: Alpha-fetoprotein; ALB: Albumin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; FBS: Fasting blood sugar; GGT: Glutamyl transpeptidase; HBeAb: Hepatitis B e-antibody; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; LAM: Lamivudine; PT: Prothrombin time; SD: Standard deviation; TB: Total bilirubin.

Citation: Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World J Gastroenterol 2021; 27(17): 2025-2038
URL: https://www.wjgnet.com/1007-9327/full/v27/i17/2025.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i17.2025